The genito-urinary system and sex hormones market in Japan stood at $1.48 billion in 2023. Forecasted data from 2024 to 2028 indicates a steady growth, with values expected to reach $1.57 billion by 2028.
The year-on-year variation from 2024 to 2028 shows consistent increments:
- 2024: $1.5 billion (+1.35%)
- 2025: $1.52 billion (+1.33%)
- 2026: $1.54 billion (+1.32%)
- 2027: $1.55 billion (+0.65%)
- 2028: $1.57 billion (+1.29%)
The Compound Annual Growth Rate (CAGR) over the next five years is expected to be approximately 1.19%, reflecting moderate but consistent market growth.
Future trends to watch for include advancements in personalized medicine, an increasing aging population, and rising awareness about hormonal treatments. Additionally, regulatory changes and technological innovations could further influence market dynamics.
